Literature DB >> 24428806

A Barrett's esophagus registry of over 1000 patients from a specialist center highlights greater risk of progression than population-based registries and high risk of low grade dysplasia.

S L Picardo1, M P O'Brien, R Feighery, D O'Toole, N Ravi, N J O'Farrell, J N O'Sullivan, J V Reynolds.   

Abstract

Barrett's esophagus (BE) arising from chronic gastro-oesophageal reflux (GERD) is the main pathologic precursor of esophageal adenocarcinoma (EAC). The risk of progression to high-grade dysplasia (HGD) and EAC is unclear, and recent population studies from Denmark and Northern Ireland suggest that this has been overestimated in the past. No data exist from the Republic of Ireland. A detailed clinical, endoscopic, and pathologic database was established in one center as a proposed pilot for a national registry, and initial and follow-up data were abstracted by a data manager. One thousand ninety-three patients were registered, 60 patients with HGD were excluded, leaving 1033, with a median age of 59 and 2 : 1 male to female ratio, and 3599 person-years of follow-up. The overall incidence of HGD/EAC was 1.33% per year overall, 0.85% if the first year is excluded. Within the first year after index endoscopy, 18 cases of HGD or EAC were identified, and 30 following the first year. Low-grade dysplasia (LGD) on index endoscopy was associated with an incidence of progression of 6.5% per year, and 3.1% when tertiary referrals were excluded. These data provide important demographic and clinical information on the population of Irish patients with BE, with incidence rates of progression higher than recently published population-based registry series, perhaps relating to sampling and pathological assessment. Low-grade dysplasia on initial biopsy is a significant proxy marker of risk of progression.
© 2014 International Society for Diseases of the Esophagus.

Entities:  

Keywords:  Barrett's esophagus; esophageal adenocarcinoma; high-grade dysplasia; low-grade dysplasia

Mesh:

Year:  2014        PMID: 24428806     DOI: 10.1111/dote.12166

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  14 in total

Review 1.  Disease Progression in Barrett's Low-Grade Dysplasia With Radiofrequency Ablation Compared With Surveillance: Systematic Review and Meta-Analysis.

Authors:  Bashar J Qumseya; Sachin Wani; Sherif Gendy; Ben Harnke; Jacques J Bergman; Herbert Wolfsen
Journal:  Am J Gastroenterol       Date:  2017-04-04       Impact factor: 10.864

Review 2.  Optimizing the diagnosis and therapy of Barrett's esophagus.

Authors:  Juan A Muñoz-Largacha; Hiran C Fernando; Virginia R Litle
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 3.  Emerging optical methods for surveillance of Barrett's oesophagus.

Authors:  Matthew B Sturm; Thomas D Wang
Journal:  Gut       Date:  2015-05-14       Impact factor: 23.059

4.  Low risk of adenocarcinoma and high-grade dysplasia in patients with non-dysplastic Barrett's esophagus: Results from a cohort from a country with low esophageal adenocarcinoma incidence.

Authors:  António Dias Pereira; Paula Chaves
Journal:  United European Gastroenterol J       Date:  2015-10-30       Impact factor: 4.623

5.  Yield of Higher-Grade Neoplasia in Barrett's Esophagus With Low-Grade Dysplasia Is Double in the First Year Following Diagnosis.

Authors:  Joel H Rubenstein; Akbar K Waljee; Ben Dwamena; Jacques Bergman; Michael Vieth; Sachin Wani
Journal:  Clin Gastroenterol Hepatol       Date:  2018-01-04       Impact factor: 11.382

Review 6.  Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Thomas M Runge; Julian A Abrams; Nicholas J Shaheen
Journal:  Gastroenterol Clin North Am       Date:  2015-04-09       Impact factor: 3.806

Review 7.  Endoscopic mucosal ablation and resection of Barrett's esophagus and related diseases.

Authors:  Juan A Muñoz-Largacha; Virginia R Litle
Journal:  J Vis Surg       Date:  2017-09-15

Review 8.  BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia.

Authors:  Cathy Bennett; Paul Moayyedi; Douglas A Corley; John DeCaestecker; Yngve Falck-Ytter; Gary Falk; Nimish Vakil; Scott Sanders; Michael Vieth; John Inadomi; David Aldulaimi; Khek-Yu Ho; Robert Odze; Stephen J Meltzer; Eamonn Quigley; Stuart Gittens; Peter Watson; Giovanni Zaninotto; Prasad G Iyer; Leo Alexandre; Yeng Ang; James Callaghan; Rebecca Harrison; Rajvinder Singh; Pradeep Bhandari; Raf Bisschops; Bita Geramizadeh; Philip Kaye; Sheila Krishnadath; M Brian Fennerty; Hendrik Manner; Katie S Nason; Oliver Pech; Vani Konda; Krish Ragunath; Imdadur Rahman; Yvonne Romero; Richard Sampliner; Peter D Siersema; Jan Tack; Tony C K Tham; Nigel Trudgill; David S Weinberg; Jean Wang; Kenneth Wang; Jennie Y Y Wong; Stephen Attwood; Peter Malfertheiner; David MacDonald; Hugh Barr; Mark K Ferguson; Janusz Jankowski
Journal:  Am J Gastroenterol       Date:  2015-04-14       Impact factor: 10.864

Review 9.  Advances in the endoscopic diagnosis and treatment of Barrett's neoplasia.

Authors:  Fergus J Q Chedgy; Kesavan Kandiah; Sreedhari Thayalasekaran; Sharmila Subramaniam; Pradeep Bhandari
Journal:  F1000Res       Date:  2016-01-28

10.  Systematic review with meta-analysis: neoplasia detection rate and post-endoscopy Barrett's neoplasia in Barrett's oesophagus.

Authors:  Nour Hamade; Amrit K Kamboj; Rajesh Krishnamoorthi; Siddharth Singh; Leslie C Hassett; David A Katzka; Charles J Kahi; Hala Fatima; Prasad G Iyer
Journal:  Aliment Pharmacol Ther       Date:  2021-07-18       Impact factor: 9.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.